Treatments for nervous disorders

Details Treatments for nervous disorders Treatments for nervous disorders

2001-08-13

2003-07-01

Fay, Zohreh (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S238800, C514S239200, C514S239500

Reexamination Certificate

active

06586427

ABSTRACT:

FIELD OF THE INVENTION
This invention describes new treatments for several nervous system disorders, including: Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addiction or Tobacco Addiction resulting in Smoking Cessation and Attention Deficit Hyperactivity Disorder (ADHD). The treatment involves the administration of the drug Reboxetine to a patient in need.
BACKGROUND
The introduction of tricyclic antidepressants in the early 1960s has provided a major advance in the treatment of neuropsychiatric disorders. Reactive and endogenous depressions, diagnoses formerly carrying grave prognostic implications, have become, with the introduction of the tricyclics, manageable disorders with a much smaller toll on the patient and the society as a whole. Electroconvulsive Shock Therapy once the only efficacious treatment in spite of its highly invasive nature, has now become, thanks to tricyclics, an obsolete form of treatment in most Countries.
The early tricyclic compounds were reuptake inhibitors of all the catecholamines released in the synaptic cleft, thus resulting in prolongation and enhancement of the dopamine (DA), noradrenaline (NA) and serotonin (5-hydroxytryptamine=5-HT) action. Desipramine, for example, has been characterized as “one of the most studied of the tricyclic anti-depressants in ADHD children and adolescents.” T. E. Wilens, et al.
Am. J. Psychiatry
153:1147-1153, 1148 (1996). It has also been considered as a treatment for the disease in adults. Id. Unfortunately, a lack of selectivity for most tricyclics, including desipramine can also cause undesired side effects particularly on the acetylcholine (especially the muscarinic component), and histamine mediated neurotransmission.
Because of these unwanted pharmacodynamic activities, cognitive impairment, sedation, urinary and gastrointestinal tract disturbances, increased intraocular pressure were limiting factors in the clinical use of these compounds and often required discontinuation of treatment. Of utmost concern were also the cardiac toxic effects and the proconvulsant activity of this group of drugs.
Another drug, methylphenidate, is also known to have clinical efficacy for the treatment of ADHD. Wender, P. H., et al.
Am. J. Psychiatry
142:547-552 (1985).
More recently, selective reuptake inhibitors for serotonin (SSRI) have been introduced with definite advantages in regard to fewer side effects without loss of efficacy.
Here we present the surprising finding that one particular drug from a new category of antidepressants, a so called noradrenaline (NA) reuptake inhibitor can be used to manage or treat a few special diseases, diseases having symptoms outside of what are usually considered depression symptoms. Now these diseases may be treated with Reboxetine.
SUMMARY OF THE INVENTION
This patent application describes the treatment of Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addition or Tobacco Addiction (with a result of Smoking Cessation or a decrease in smoking) and Attention Deficit Hyperactivity Disorder (ADHD), comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and of pharmaceutically acceptable salts thereof to a patient.
Reboxetine is the generic name of the pharmaceutical substance with the chemical name of 2-(I-((2-ethoxyphenoxy)benzyl)-morpholine, and its pharmaceutically acceptable salts. Reboxetine can be a free base, or it can include reboxetine methanesulfonate (also called reboxetine mesylate) or any other pharmaceutically acceptable salt that does not significantly affect the pharmaceutical activity of the substance.
A preferred dose range is 4 to 10 mg per patient per day and the most preferred dose is 6 to 8 mg or 8 to 10 mg per patient daily, depending upon the patient, delivered twice a day (b.i.d.).


REFERENCES:
patent: 4229449 (1980-10-01), Meloni et al.
patent: 5068433 (1991-11-01), Meloni et al.
patent: 5391735 (1995-02-01), Meloni et al.
patent: 6046193 (2000-04-01), Heiligenstein
patent: 0 534 756 (1993-03-01), None
patent: 0 721 777 (1996-07-01), None
patent: 0 756 869 (1996-07-01), None
patent: WO 96/12485 (1996-05-01), None
patent: WO 99/15177 (1999-04-01), None
patent: WO 99/52531 (1999-10-01), None
patent: 93/0694 (1993-07-01), None
A. Dubini et al., “Do noradrealine and serotonin differentially affect social motivation and behavior?”, European Neuropyschopharmacology, vol. 7, Supp. 1, pp. s49-s55 (1997).
J. Elia et al., “Stimulant drug treatment of hyperactivity: Biochemical correlates,” Clin Pharmacol Term, vol. 48, pp. 57-66 (1990).
R.J. Frances et al., “Alcohol and Other Psychoative Substance Use Disorders,” The American Psychiatric Press Textbook of Psychiatry, 2d Ed., pp. 355-410 (1994).
D.R. Gastfriend et al., “Desipramine in the treatment of attention deficit order in adolescents,” Psychopharmacology Bulletin, vol. 21, No. 1, pp. 144-145 (1985).
C. Kornetsky, “Psychoactive Drugs in the Immature Organism,” Psychopharmacologia, vol. 17, pp. 105-136 (1970).
B.E. Leonard, “Noradrenaline in basic models of depression,” European Neuropsychopharmacology, vol. 7, No. Suppl. 1, pp. s11-s16.
R.A. Pleak et al., “Effects of venlafaxine treatment for ADHD in a child,” Am. J. Psychiatry, vol. 152, No. 7, p. 1099 (Jul. 1995).
C.W. Popper et al., “Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence,” The American Psychiatric Press Textbook of Psychiatry, 2d Ed., pp. 729-832 (1994).
R.I. Shader, “Hypnosis,” Manual of Physciatric Therapeutics, 2d Ed., pp. 81-85 (Chapter 11).
J. Svestka, “Antidepressives of the 3rd, 4th, and 5thgeneration,” Cesk-Phychiatr., vol. 90, No. 1, pp. 3-19 (Feb. 1994). (Czech).
P.H. Wender, “Hypnosis,” Manual of Phyciatric Therapeutics, 2d Ed., pp. 167-179, (Chapter 18).
P.H. Wender et al., “A Controlled Study of Methyphenidate in the Treatment of attention Deficit Disorder, Residual Type, in Adults,” Am. J. Psychiatry, vol. 142, pp. 547-552 (May 1985).
T.E. Wilens et al., “Pharmacotherapy of attention deficit hyperactivity disorder”. Current opinions in CPNS Investigational Drugs, vol. 1 pp. 453-465 (1999).
T.E. Wilens et al., “Six-Week, Double-Blind, Placebo-Controlled Study of Desipramine for Adult Attention Deficit Hyperactivity Disorder,” Am. J. Psychiatr,Y vol. 153, pp. 1147-1153 (Sep. 1996).
A.J. Zametkin et al., “Neurobiology of Attention Deficit Disorder With Hyperactivity: Where Have We Come in 50 Years?”, J. Am. Academy Child Adolesc Psychiatry, vol. 26, pp. 676-686 (Apr. 1987).
A.J. Zametkin et al., “Noradrenergic Hypothesis of Attention Deficit Disorder with Hyperactivity: A Critical Review,” Psychopharmacology: The Third Generation of Progress, pp. 837-842 (1987).
International Search Report in PCT/US99/04289 dated Sep. 13, 1999.
Written Opinion in PCT/US99/04289 dated Feb. 7, 2000.

Affiliated with

Also associated with

Rating

Treatments for nervous disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatments for nervous disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatments for nervous disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3082959